Clinical	B:C1837514
heterogeneity	I:C1837514
of	O
LRRK2	O
p.I2012T	I:C1425650
mutation	O
.	O

Clinical	O
heterogeneity	I:C1837514
of	O
LRRK2	B:C1425650
p.I2012T	I:C1425650
mutation	O
.	O

Clinical	O
heterogeneity	I:C1837514
of	O
LRRK2	O
p.I2012T	I:C1425650
mutation	B:C0026882
.	O

Leucine	B:C1425650
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
(	O
Leucine	O
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
)	O
mutations	O
are	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
.	O

Leucine	O
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
(	O
Leucine	B:C1425650
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
)	O
mutations	O
are	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
.	O

Leucine	O
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
(	O
Leucine	O
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
)	O
mutations	B:C0026882
are	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
.	O

Leucine	O
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
(	O
Leucine	O
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
)	O
mutations	O
are	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
.	O

Leucine	O
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
(	O
Leucine	O
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
)	O
mutations	O
are	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
)	O
.	O

However	O
,	O
only	O
few	O
cases	O
carrying	O
Leucine	B:C1425650
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
mutations	O
have	O
been	O
reported	O
in	O
Taiwanese	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
.	O

However	O
,	O
only	O
few	O
cases	O
carrying	O
Leucine	O
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
mutations	B:C0026882
have	O
been	O
reported	O
in	O
Taiwanese	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
.	O

However	O
,	O
only	O
few	O
cases	O
carrying	O
Leucine	O
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
mutations	O
have	O
been	O
reported	O
in	O
Taiwanese	B:C1556096
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
.	O

However	O
,	O
only	O
few	O
cases	O
carrying	O
Leucine	O
-	I:C1425650
rich	I:C1425650
repeat	I:C1425650
kinase	I:C1425650
2	I:C1425650
mutations	O
have	O
been	O
reported	O
in	O
Taiwanese	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
patients	O
.	O

We	O
used	O
targeted	O
next	B:C2936622
generation	I:C2936622
sequencing	I:C2936622
(	O
next	O
generation	I:C2936622
sequencing	I:C2936622
)	O
,	O
covering	O
24	O
candidate	O
genes	I:C1332838
involved	O
in	O
neurodegenerative	O
disorders	I:C0524851
,	O
to	O
analyze	O
40	O
probands	O
with	O
familial	O
PD	I:C0030567
,	O
and	O
10	O
patients	O
with	O
mixed	O
neurodegenerative	O
disorders	I:C0524851
.	O

We	O
used	O
targeted	O
next	O
generation	I:C2936622
sequencing	I:C2936622
(	O
next	B:C2936622
generation	I:C2936622
sequencing	I:C2936622
)	O
,	O
covering	O
24	O
candidate	O
genes	I:C1332838
involved	O
in	O
neurodegenerative	O
disorders	I:C0524851
,	O
to	O
analyze	O
40	O
probands	O
with	O
familial	O
PD	I:C0030567
,	O
and	O
10	O
patients	O
with	O
mixed	O
neurodegenerative	O
disorders	I:C0524851
.	O

We	O
used	O
targeted	O
next	O
generation	I:C2936622
sequencing	I:C2936622
(	O
next	O
generation	I:C2936622
sequencing	I:C2936622
)	O
,	O
covering	O
24	O
candidate	B:C1332838
genes	I:C1332838
involved	O
in	O
neurodegenerative	O
disorders	I:C0524851
,	O
to	O
analyze	O
40	O
probands	O
with	O
familial	O
PD	I:C0030567
,	O
and	O
10	O
patients	O
with	O
mixed	O
neurodegenerative	O
disorders	I:C0524851
.	O

We	O
used	O
targeted	O
next	O
generation	I:C2936622
sequencing	I:C2936622
(	O
next	O
generation	I:C2936622
sequencing	I:C2936622
)	O
,	O
covering	O
24	O
candidate	O
genes	I:C1332838
involved	O
in	O
neurodegenerative	B:C0524851
disorders	I:C0524851
,	O
to	O
analyze	O
40	O
probands	O
with	O
familial	O
PD	I:C0030567
,	O
and	O
10	O
patients	O
with	O
mixed	O
neurodegenerative	O
disorders	I:C0524851
.	O

We	O
used	O
targeted	O
next	O
generation	I:C2936622
sequencing	I:C2936622
(	O
next	O
generation	I:C2936622
sequencing	I:C2936622
)	O
,	O
covering	O
24	O
candidate	O
genes	I:C1332838
involved	O
in	O
neurodegenerative	O
disorders	I:C0524851
,	O
to	O
analyze	O
40	O
probands	O
with	O
familial	B:C0030567
PD	I:C0030567
,	O
and	O
10	O
patients	O
with	O
mixed	O
neurodegenerative	O
disorders	I:C0524851
.	O

We	O
used	O
targeted	O
next	O
generation	I:C2936622
sequencing	I:C2936622
(	O
next	O
generation	I:C2936622
sequencing	I:C2936622
)	O
,	O
covering	O
24	O
candidate	O
genes	I:C1332838
involved	O
in	O
neurodegenerative	O
disorders	I:C0524851
,	O
to	O
analyze	O
40	O
probands	O
with	O
familial	O
PD	I:C0030567
,	O
and	O
10	O
patients	O
with	O
mixed	O
neurodegenerative	B:C0524851
disorders	I:C0524851
.	O

Sanger	B:C1511897
sequencing	I:C1511897
of	O
the	O
identified	O
mutation	O
in	O
the	O
first	O
set	O
of	O
the	O
study	O
was	O
performed	O
in	O
additional	O
270	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
,	O
including	O
139	O
familial	O
PD	I:C0030567
and	O
131	O
early	O
-	I:C1833334
onset	I:C1833334
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
onset	O
age	O
less	O
than	O
50	O
years	O
old	O
)	O
,	O
and	O
300	O
age	O
/	O
gender	O
matched	O
control	O
subjects	O
.	O

Sanger	O
sequencing	I:C1511897
of	O
the	O
identified	O
mutation	B:C0026882
in	O
the	O
first	O
set	O
of	O
the	O
study	O
was	O
performed	O
in	O
additional	O
270	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
,	O
including	O
139	O
familial	O
PD	I:C0030567
and	O
131	O
early	O
-	I:C1833334
onset	I:C1833334
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
onset	O
age	O
less	O
than	O
50	O
years	O
old	O
)	O
,	O
and	O
300	O
age	O
/	O
gender	O
matched	O
control	O
subjects	O
.	O

Sanger	O
sequencing	I:C1511897
of	O
the	O
identified	O
mutation	O
in	O
the	O
first	O
set	O
of	O
the	O
study	O
was	O
performed	O
in	O
additional	O
270	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
patients	O
,	O
including	O
139	O
familial	O
PD	I:C0030567
and	O
131	O
early	O
-	I:C1833334
onset	I:C1833334
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
onset	O
age	O
less	O
than	O
50	O
years	O
old	O
)	O
,	O
and	O
300	O
age	O
/	O
gender	O
matched	O
control	O
subjects	O
.	O

Sanger	O
sequencing	I:C1511897
of	O
the	O
identified	O
mutation	O
in	O
the	O
first	O
set	O
of	O
the	O
study	O
was	O
performed	O
in	O
additional	O
270	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
,	O
including	O
139	O
familial	B:C0030567
PD	I:C0030567
and	O
131	O
early	O
-	I:C1833334
onset	I:C1833334
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
onset	O
age	O
less	O
than	O
50	O
years	O
old	O
)	O
,	O
and	O
300	O
age	O
/	O
gender	O
matched	O
control	O
subjects	O
.	O

Sanger	O
sequencing	I:C1511897
of	O
the	O
identified	O
mutation	O
in	O
the	O
first	O
set	O
of	O
the	O
study	O
was	O
performed	O
in	O
additional	O
270	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
,	O
including	O
139	O
familial	O
PD	I:C0030567
and	O
131	O
early	B:C1833334
-	I:C1833334
onset	I:C1833334
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
onset	O
age	O
less	O
than	O
50	O
years	O
old	O
)	O
,	O
and	O
300	O
age	O
/	O
gender	O
matched	O
control	O
subjects	O
.	O

Sanger	O
sequencing	I:C1511897
of	O
the	O
identified	O
mutation	O
in	O
the	O
first	O
set	O
of	O
the	O
study	O
was	O
performed	O
in	O
additional	O
270	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
,	O
including	O
139	O
familial	O
PD	I:C0030567
and	O
131	O
early	O
-	I:C1833334
onset	I:C1833334
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
(	O
onset	O
age	O
less	O
than	O
50	O
years	O
old	O
)	O
,	O
and	O
300	O
age	O
/	O
gender	O
matched	O
control	O
subjects	O
.	O

We	O
found	O
a	O
missense	B:C0599155
variant	I:C0599155
,	O
p.I2012T	O
,	O
in	O
the	O
LRRK2	O
gene	I:C1425650
in	O
one	O
sporadic	O
patient	O
having	O
early	O
-	I:C1833334
onset	I:C1833334
frontotemporal	O
dementia	I:C0338451
with	O
parkinsonism	O
and	O
dystonia	O
.	O

We	O
found	O
a	O
missense	O
variant	I:C0599155
,	O
p.I2012T	B:C0017337
,	O
in	O
the	O
LRRK2	O
gene	I:C1425650
in	O
one	O
sporadic	O
patient	O
having	O
early	O
-	I:C1833334
onset	I:C1833334
frontotemporal	O
dementia	I:C0338451
with	O
parkinsonism	O
and	O
dystonia	O
.	O

We	O
found	O
a	O
missense	O
variant	I:C0599155
,	O
p.I2012T	O
,	O
in	O
the	O
LRRK2	B:C1425650
gene	I:C1425650
in	O
one	O
sporadic	O
patient	O
having	O
early	O
-	I:C1833334
onset	I:C1833334
frontotemporal	O
dementia	I:C0338451
with	O
parkinsonism	O
and	O
dystonia	O
.	O

We	O
found	O
a	O
missense	O
variant	I:C0599155
,	O
p.I2012T	O
,	O
in	O
the	O
LRRK2	O
gene	I:C1425650
in	O
one	O
sporadic	O
patient	O
having	O
early	B:C1833334
-	I:C1833334
onset	I:C1833334
frontotemporal	O
dementia	I:C0338451
with	O
parkinsonism	O
and	O
dystonia	O
.	O

We	O
found	O
a	O
missense	O
variant	I:C0599155
,	O
p.I2012T	O
,	O
in	O
the	O
LRRK2	O
gene	I:C1425650
in	O
one	O
sporadic	O
patient	O
having	O
early	O
-	I:C1833334
onset	I:C1833334
frontotemporal	B:C0338451
dementia	I:C0338451
with	O
parkinsonism	O
and	O
dystonia	O
.	O

We	O
found	O
a	O
missense	O
variant	I:C0599155
,	O
p.I2012T	O
,	O
in	O
the	O
LRRK2	O
gene	I:C1425650
in	O
one	O
sporadic	O
patient	O
having	O
early	O
-	I:C1833334
onset	I:C1833334
frontotemporal	O
dementia	I:C0338451
with	O
parkinsonism	B:C0242422
and	O
dystonia	O
.	O

We	O
found	O
a	O
missense	O
variant	I:C0599155
,	O
p.I2012T	O
,	O
in	O
the	O
LRRK2	O
gene	I:C1425650
in	O
one	O
sporadic	O
patient	O
having	O
early	O
-	I:C1833334
onset	I:C1833334
frontotemporal	O
dementia	I:C0338451
with	O
parkinsonism	O
and	O
dystonia	B:C0013421
.	O

Sanger	B:C1511897
sequencing	I:C1511897
this	O
substitution	O
in	O
additional	O
270	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
in	O
the	O
second	O
set	O
of	O
the	O
study	O
revealed	O
two	O
additional	O
variant	O
carriers	O
:	O
one	O
having	O
autosomal	O
-	I:C0030567
dominant	I:C0030567
familial	I:C0030567
PD	I:C0030567
,	O
and	O
one	O
with	O
sporadic	O
PD	I:C0030567
.	O

Sanger	O
sequencing	I:C1511897
this	O
substitution	O
in	O
additional	O
270	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
patients	O
in	O
the	O
second	O
set	O
of	O
the	O
study	O
revealed	O
two	O
additional	O
variant	O
carriers	O
:	O
one	O
having	O
autosomal	O
-	I:C0030567
dominant	I:C0030567
familial	I:C0030567
PD	I:C0030567
,	O
and	O
one	O
with	O
sporadic	O
PD	I:C0030567
.	O

Sanger	O
sequencing	I:C1511897
this	O
substitution	O
in	O
additional	O
270	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
in	O
the	O
second	O
set	O
of	O
the	O
study	O
revealed	O
two	O
additional	O
variant	B:C0678941
carriers	O
:	O
one	O
having	O
autosomal	O
-	I:C0030567
dominant	I:C0030567
familial	I:C0030567
PD	I:C0030567
,	O
and	O
one	O
with	O
sporadic	O
PD	I:C0030567
.	O

Sanger	O
sequencing	I:C1511897
this	O
substitution	O
in	O
additional	O
270	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
in	O
the	O
second	O
set	O
of	O
the	O
study	O
revealed	O
two	O
additional	O
variant	O
carriers	B:C0007294
:	O
one	O
having	O
autosomal	O
-	I:C0030567
dominant	I:C0030567
familial	I:C0030567
PD	I:C0030567
,	O
and	O
one	O
with	O
sporadic	O
PD	I:C0030567
.	O

Sanger	O
sequencing	I:C1511897
this	O
substitution	O
in	O
additional	O
270	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
in	O
the	O
second	O
set	O
of	O
the	O
study	O
revealed	O
two	O
additional	O
variant	O
carriers	O
:	O
one	O
having	O
autosomal	B:C0030567
-	I:C0030567
dominant	I:C0030567
familial	I:C0030567
PD	I:C0030567
,	O
and	O
one	O
with	O
sporadic	O
PD	I:C0030567
.	O

Sanger	O
sequencing	I:C1511897
this	O
substitution	O
in	O
additional	O
270	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
patients	O
in	O
the	O
second	O
set	O
of	O
the	O
study	O
revealed	O
two	O
additional	O
variant	O
carriers	O
:	O
one	O
having	O
autosomal	O
-	I:C0030567
dominant	I:C0030567
familial	I:C0030567
PD	I:C0030567
,	O
and	O
one	O
with	O
sporadic	B:C0030567
PD	I:C0030567
.	O

The	O
p.I2012T	B:C0017337
substitution	O
was	O
absent	O
in	O
300	O
normal	O
control	O
subjects	O
.	O

Analyzing	O
family	O
members	O
of	O
the	O
proband	O
with	O
p.I2012T	B:C0017337
revealed	O
co-segregation	O
of	O
the	O
variant	O
and	O
parkinsonism	O
.	O

Analyzing	O
family	O
members	O
of	O
the	O
proband	O
with	O
p.I2012T	O
revealed	O
co-segregation	O
of	O
the	O
variant	B:C4284334
and	O
parkinsonism	O
.	O

Analyzing	O
family	O
members	O
of	O
the	O
proband	O
with	O
p.I2012T	O
revealed	O
co-segregation	O
of	O
the	O
variant	O
and	O
parkinsonism	B:C0242422
.	O

Clinical	O
presentations	O
,	O
levodopa	B:C0023570
responses	O
,	O
and	O
(	O
Tc99	I:C0535449
m	I:C0535449
)	I:C0535449
TRODAT	I:C0535449
-	O
SPECT	O
imaging	O
findings	O
of	O
this	O
index	O
family	O
were	O
similar	O
to	O
idiopathic	O
PD	I:C0030567
.	O

Clinical	O
presentations	O
,	O
levodopa	O
responses	B:C0683154
,	O
and	O
(	O
Tc99	I:C0535449
m	I:C0535449
)	I:C0535449
TRODAT	I:C0535449
-	O
SPECT	O
imaging	O
findings	O
of	O
this	O
index	O
family	O
were	O
similar	O
to	O
idiopathic	O
PD	I:C0030567
.	O

Clinical	O
presentations	O
,	O
levodopa	O
responses	O
,	O
and	O
(	B:C0535449
Tc99	I:C0535449
m	I:C0535449
)	I:C0535449
TRODAT	I:C0535449
-	O
SPECT	O
imaging	O
findings	O
of	O
this	O
index	O
family	O
were	O
similar	O
to	O
idiopathic	O
PD	I:C0030567
.	O

Clinical	O
presentations	O
,	O
levodopa	O
responses	O
,	O
and	O
(	O
Tc99	I:C0535449
m	I:C0535449
)	I:C0535449
TRODAT	I:C0535449
-	O
SPECT	O
imaging	O
findings	O
of	O
this	O
index	O
family	O
were	O
similar	O
to	O
idiopathic	B:C0030567
PD	I:C0030567
.	O

Our	O
results	O
revealed	O
clinical	B:C1837514
heterogeneity	I:C1837514
of	O
the	O
LRRK2	O
p.I2012T	I:C1425650
substitution	O
,	O
and	O
demonstrated	O
the	O
use	O
of	O
targeted	O
next	O
generation	I:C2936622
sequencing	I:C2936622
for	O
genetic	O
diagnosis	O
in	O
multiplex	O
families	O
with	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
or	O
mixed	O
neurodegenerative	O
disorders	I:C0524851
.	O

Our	O
results	O
revealed	O
clinical	O
heterogeneity	I:C1837514
of	O
the	O
LRRK2	B:C1425650
p.I2012T	I:C1425650
substitution	O
,	O
and	O
demonstrated	O
the	O
use	O
of	O
targeted	O
next	O
generation	I:C2936622
sequencing	I:C2936622
for	O
genetic	O
diagnosis	O
in	O
multiplex	O
families	O
with	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
or	O
mixed	O
neurodegenerative	O
disorders	I:C0524851
.	O

Our	O
results	O
revealed	O
clinical	O
heterogeneity	I:C1837514
of	O
the	O
LRRK2	O
p.I2012T	I:C1425650
substitution	O
,	O
and	O
demonstrated	O
the	O
use	O
of	O
targeted	O
next	B:C2936622
generation	I:C2936622
sequencing	I:C2936622
for	O
genetic	O
diagnosis	O
in	O
multiplex	O
families	O
with	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
or	O
mixed	O
neurodegenerative	O
disorders	I:C0524851
.	O

Our	O
results	O
revealed	O
clinical	O
heterogeneity	I:C1837514
of	O
the	O
LRRK2	O
p.I2012T	I:C1425650
substitution	O
,	O
and	O
demonstrated	O
the	O
use	O
of	O
targeted	O
next	O
generation	I:C2936622
sequencing	I:C2936622
for	O
genetic	O
diagnosis	O
in	O
multiplex	O
families	O
with	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
or	O
mixed	O
neurodegenerative	O
disorders	I:C0524851
.	O

Our	O
results	O
revealed	O
clinical	O
heterogeneity	I:C1837514
of	O
the	O
LRRK2	O
p.I2012T	I:C1425650
substitution	O
,	O
and	O
demonstrated	O
the	O
use	O
of	O
targeted	O
next	O
generation	I:C2936622
sequencing	I:C2936622
for	O
genetic	O
diagnosis	O
in	O
multiplex	O
families	O
with	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
or	O
mixed	O
neurodegenerative	B:C0524851
disorders	I:C0524851
.	O

